The biosynthesis of adrenal corticosteroids in humans depends on a continuous supply of cholesterol, which can be derived from both local synthesis and receptor-mediated uptake of low density lipoproteins (LDL) from plasma.
The biosynthesis of adrenal corticosteroids requires a continuous supply of cholesterol, which can be derived from both de novo biosynthesis within the gland and from the uptake of plasma lipoproteins (1) (2) (3) (4) (5) . In human subjects, cholesterol contained in low density lipoproteins (LDL) is used in preference to other lipoprotein particles, and receptor-mediated uptake of LDL is believed to be an important source of cholesterol for corticotropin (ACTH)-stimulated adrenal corticosteroid production (2) (3) (4) (5) .
Recent studies in patients with abetalipoproteinemia (6, 7) and homozygous familial hypercholesterolemia (FH) (8) have provided evidence to support the view that LDL is an important source of cholesterol for adrenal corticosteroid synthesis during prolonged stimulation with ACTH. In these studies, parameters of adrenal cortical function were normal in the basal state but the response to ACTH was mildly impaired; this suggests that the lack of either LDL or specific high-affinity LDL receptors impairs the delivery of cholesterol to the adrenal cortex under conditions of maximal stimulation. In contrast to these studies, the adrenal cortical response to ACTH is normal in patients with heterozygous FH (9) . The relative contributions of receptor-mediated uptake of LDL as compared to de novo cholesterol biosynthesis within the adrenal gland of patients with heterozygous FH is, however, unknown.
Two specific inhibitors of the rate-limiting enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglutaryl-CoA reductase [HMG-CoA reductase; mevalonate:NAD+ oxidoreductase (CoA-acylating), EC 1.1.1.88], mevinolin (10) (11) (12) and compactin (13) (14) (15) have recently been described. Both agents are active in milligram quantities and are potent hypocholesterolemic agents in experimental animals (12) and in both normal human volunteers (11) and patients with heterozygous FH (13) (14) (15) (16) (17) (18) . Because of the possibility that mevinolin, in clinically effective doses, may influence cholesterol biosynthesis in the adrenal cortex, thereby potentially leading to an impairment in adrenal corticosteroid production in patients with genetic abnormalities at the LDL receptor locus, we have evaluated the adrenal cortical response to prolonged ACTH stimulation in eight patients with well-characterized heterozygous FH studied under both basal conditions and during therapy with optimal doses of mevinolin.
METHODS
Study Subjects. All studies were conducted in the Clinical Research Center of The Oregon Health Sciences University. Informed consent was obtained from all patients and the protocol was approved by the Human Research Committee of this institution. The subjects consisted of eight patients with well-characterized heterozygous FH in whom currently available lipid-lowering medications had failed to lower serum cholesterol concentrations below 300 mg/dl. In all patients, the diagnosis of heterozygous FH was based on primary hypercholesterolemia, an inheritance pattern consistent with autosomal dominant, tendon xanthomas, and the presence of primary hypercholesterolemia in other family members with an absence of multiple phenotypes in other relatives. The characteristics of the study subjects (four males and four females) are outlined in urine-free cortisol and serum cortisol were determined by radioimmunoassay as described (7) (8) (9) . The adrenal response to ACTH was determined during a 36-hr continuous infusion of a-ACTH-(1-24) (Cortrosyn) in 5% glucose at a rate of 3.3 units/hr (20) . This infusion rate produces plasma ACTH concentrations that are at least 2 times higher than those needed to ensure maximum stimulation of adrenal cortisol production (21) (22) (23) . Patients (24) .
RESULTS
The concentrations of plasma lipids and lipoproteins in the eight patients prior to therapy with mevinolin and again at the time of the repeat ACTH infusion are shown in Table 2 . In four of the patients, optimal reduction of plasma total and LDL cholesterol was obtained on 40 mg of mevinolin per day (20 mg twice daily), whereas in the other four patients further decreases in the concentrations of LDL cholesterol were obtained when the dose was increased to 40 mg twice daily. In all cases, patients were studied under steady-state conditions after a minimum of 4 weeks on optimal doses of single drug therapy with mevinolin, and the total duration of mevinolin therapy ranged from 16 to 34 weeks (Table 2) .
To determine whether therapy with mevinolin was associated with any impairment in steroid hormone production in vivo, the adrenal response to ACTH stimulation was evaluated in each patient prior to therapy with mevinolin and again under steady-state conditions on optimal doses of mevinolin. In each case, the adrenal response to a continuous 36-hr infusion of a-ACTH-(1-24) (Cortrosyn) was determined. The initial concentrations of serum cortisol were similar in patients before and during mevinolin therapy, and, as illustrated in Fig. 1 , rapid increases in the concentrations of serum cortisol occurred in response to ACTH stimulation in the patients under both basal conditions and during therapy with mevinolin. Under both circumstances, serum concentrations of cortisol increased rapidly over the first 4-6 hr of ACTH infusion and then showed a much slower but progressive increase. Although the mean serum concentrations ofcortisol obtained during mevinolin therapy were slightly higher than those obtained under basal conditions, the difference is not statistically significant. Changes in the rates of urinary excretion of free cortisol were also determined in timed collections obtained during ACTH stimulation under basal conditions and upon restudy while the patients were taking mevinolin. As illustrated in Fig. 2 , excretion of urine-free cortisol over three consecutive 12-hr time periods as well as the cumulative 36-hr excretion was similar under both circumstances. On an individual basis, total excretion of urinefree cortisol over the 36-hr period of ACTH stimulation decreased in six patients and increased in two during mevinolin therapy, as compared to the rates of excretion during ACTH stimulation under basal conditions.
DISCUSSION
The production of adrenal corticosteroids during prolonged ACTH infusion requires a continuous supply of cholesterol, which can be derived from both local synthesis and receptormediated uptake of LDL (1) (2) (3) (4) (5) . Previous studies have established that the adrenal cortical response to prolonged ACTH infusion is impaired in patients with both abetalipoproteinemia (6, 7) and homozygous FH (8), but it is normal in patients with heterozygous FH (9) . The relative contributions of de novo cholesterol biosynthesis and receptor-mediated uptake of LDL in the provision of adrenal cholesterol in patients with the latter disorder is, however, unknown. The purpose of the present study was to determine whether or not clinically effective doses of mevinolin, a specific inhibitor of HMG-CoA reductase, influences the adrenal cortical response to prolonged stimulation with ACTH in patients with heterozygous FH.
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